




## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 :	A1	(11) International Publication Number: WO 93/14762
A61K 31/56		(43) International Publication Date: 5 August 1993 (05.08.93)

(21) International Application Number: PCT/US93/00409	(74) Agent: MITRI, Salvatore, C.; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).
(22) International Filing Date: 21 January 1993 (21.01.93)	
(30) Priority data: 826,342 27 January 1992 (27.01.92) US	(81) Designated States: AU, BB, BG, BR, FI, HU, JP, KR, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG).
(71) Applicant: MERCK & CO., INC. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).	
(72) Inventors: RASMUSSEN, Gary, H. ; 155 Park Place, Watchung, NJ 07060 (US). SALZMANN, Thomas, N. ; 154 Meadowbrook Drive, North Plainfield, NJ 07062 (US). STEINBERG, Nathan, G. ; 405 Willow Way, Clark, NJ 07666 (US).	Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>

(54) Title: 17 $\beta$ -HYDROXYBENZOYL-4-AZA-5 $\alpha$ -ANDROST-1-EN-3-ONES USEFUL TO TREAT BALDNESS

## (57) Abstract

17 $\beta$ -hydroxybenzoyl-4-aza-5 $\alpha$ -androst-1-en-3-ones useful to treat baldness have formula (I), wherein R is selected from hydrogen, methyl and ethyl and R<sup>2</sup> is phenyl substituted with one or more of: -OH, -OC<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkyl, -(CH<sub>2</sub>)<sub>m</sub>H, -(CH<sub>2</sub>)<sub>n</sub>COOH, including protected -OH, where m is 1-4, n is 1-3, and providing C<sub>1</sub>-C<sub>4</sub> alkyl is only present when one of the above oxygen containing radicals is present, wherein the dotted line represents a double bond which can be present, pharmaceutically acceptable salts and esters thereof, and a pharmaceutical formulation thereof.

Best Available Copy

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CC	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LJ	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TG	Togo
DE	Germany	MG	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

5

-1-

10

TITLE OF THE INVENTION

17 $\beta$ -HYDROXYBENZOYL-4-AZA-5 $\alpha$ -ANDROST-  
1-EN-3-ONES USEFUL TO TREAT BALDNESS

15

BACKGROUND OF THE INVENTION

The present invention is directed to 17 $\beta$ -hydroxybenzoyl-4-aza-5 $\alpha$ -androst-1-en-3-ones and related compounds which are useful to treat baldness.

20

DESCRIPTION OF THE PRIOR ART

The art discloses that certain undesirable physiological manifestations, such as acne vulgaris, seborrhea, female hirsutism, and male pattern baldness and benign prostatic hypertrophy, are the result of hyperandrogenic stimulation caused by an excessive accumulation of testosterone or similar androgenic hormones in the metabolic system.

30

-2-

Early attempts to provide a chemotherapeutic agent to counter the undesirable results of hyperandrogenicity resulted in the discovery of several steroidal antiandrogens having undesirable 5 hormonal activities of their own. The estrogens, for example, not only counteract the effect of the androgens but have a feminizing effect as well. Non-steroidal antiandrogens have also been developed, for example, 4'-nitro-3'-trifluoromethylisobutyranilide. See Neri et al., Endo., Vol. 91, No. 2 (1972). However, these products, though devoid of 10 hormonal effects, are peripherally active, competing with the natural androgens for receptor sites, and hence have a tendency to feminize a male host or the 15 male fetus of a female host.

More recently, it became known that the principal mediator of androgenic activity in some target organs is  $5\alpha$ -dihydrotestosterone and that it is formed locally in the target organ 20 by the action of testosterone- $5\alpha$ -reductase. Therefore, it has been postulated and demonstrated that inhibitors of testosterone- $5\alpha$ -reductase will serve to prevent or lessen symptoms of hyperandrogenic stimulation. Nayfe et al., Steroids, 25 14, 269 (1969) demonstrated in vitro that methyl 4-androsten-3-one- $17\beta$ -carboxylate was a testosterone- $5\alpha$ -reductase inhibitor. Subsequently, Voigt and Hsia, Endocrinology, 92, 1216 (1973), Canadian Pat. No. 970,692, demonstrated that the 30 above ester and the parent free acid, 4-androsten-3-one- $17\beta$ -carboxylic acid, are both active inhibitors of testosterone- $5\alpha$ -reductase in vitro.

-3-

They further demonstrated that topical application of either testosterone or  $5\alpha$ -dihydrotestosterone caused enlargement of the female hamster flank organ, an androgen dependent sebaceous structure. However, 5 concomitant administration of 4-androsten-3-one-17 $\beta$ -carboxylic acid or its methyl ester inhibited the response elicited by testosterone but did not inhibit the response elicited by  $5\alpha$ -dihydrotestosterone.

These results were interpreted as indicating that 10 the compounds were antiandrogenic by virtue of their ability to inhibit testosterone- $5\alpha$ -reductase.

A number of 4-aza steroid compounds are known. See, for example, U.S. Pat. Nos. 2,227,876; 3,239,417; 3,264,301; and 3,285,918; French Pat. No. 15 1,465,544; Doorenbos and Solomons, J. Pharm. Sci. 62, 4, pp. 638-640 (1973); Doorenbos and Brown, J. Pharm. Sci., 60 8, pp. 1234-1235 (1971); and Doorenbos and Kim, J. Pharm. Sci. 63, 4, pp. 620-622 (1974).

In addition, U.S. Patents 4,377,584, 20 4,220,775, 4,859,681, and 4,760,071, the articles in J. Med. Chem. 27, p. 1690-1701 (1984) and J. Med. Chem. 29, 2998-2315 (1986) of Rasmusson *et al.*, U.S. Patent 4,845,104 to Carlin *et al.* and U.S. Patent 4,732,897 to Cainelli, *et al.* describe 4-aza-25 17 $\beta$ -substituted- $5\alpha$ -androstan-3-ones which are said to be useful in the treatment of hyperandrogenic conditions. However, none of these publications suggest that any of the 17 $\beta$ N-(monosubstituted)-carbamoyl-4-aza- $5\alpha$ -androsten-1-en-3-ones of the 30 present invention would have utility in the treatment of baldness.

-4-


SUMMARY OF THE INVENTION

The present invention is directed toward using

17 $\beta$ -hydroxybenzoyl-carbamoyl-4-aza-5 $\alpha$ -androst-1-en-3-ones and related compounds, to treat baldness. The 17 $\beta$ -substituted benzoyl-4-aza-5 $\alpha$ -androst-1-en-3-one compounds of the invention have the formula:

10

15



20

wherein

R is selected from hydrogen, methyl and ethyl and R<sup>2</sup> is phenyl substituted with one or more of: -OH,

-COOH, -OC<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkyl,

- $(CH_2)_mOH$ , - $(CH_2)_nCOOH$ , including protected OH, where m is 1-4, n is 1-3, providing

C<sub>1</sub>-C<sub>4</sub> alkyl is only present when one of the above oxygen-containing radicals is present,

25

30


-5-

wherein the dotted line represents a double bond which can be present, and pharmaceutically acceptable salts and esters thereof.

5 Preferred embodiments of these 17 $\beta$ -acyl compounds are represented by the formula:

10

15



wherein

20 R is hydrogen, methyl or ethyl, and  
R<sup>2</sup> is phenyl substituted with one or more -OH groups on the 2, 3, 4 or 5 positions of the phenyl ring.

25 Representative of these compounds are the following:

17 $\beta$ -(4-hydroxyphenyl)-4-aza-5 $\alpha$ -androst-1-en-3-one;  
17 $\beta$ -(3-hydroxyphenyl)-4-aza-5 $\alpha$ -androst-1-en-3-one;  
30 17 $\beta$ -(3,4-dihydroxyphenyl)-4-aza-5 $\alpha$ -androst-1-en-3-one;  
17 $\beta$ -(3,5-dimethyl-4-hydroxyphenyl)-4-aza-5 $\alpha$ -androst-1-en-3-one;

-6-

17 $\beta$ -(4-hydroxymethylphenyl)-4-aza-5 $\alpha$ -androst-1-en-3-one;  
17 $\beta$ -(2-hydroxyethylphenylcarbonyl)-4-aza-5 $\alpha$ -androst-1-en-3-one;  
5 17 $\beta$ -(4-methoxyphenyl)-4-aza-5 $\alpha$ -androst-1-en-3-one;  
;  
17 $\beta$ -(4-carboxymethylphenyl)-4-aza-5 $\alpha$ -androst-1-en-3-one;  
10 17 $\beta$ -(4-hydroxyphenyl)-4-aza-4-methyl-5 $\alpha$ -androst-1-en-3-one;  
17 $\beta$ -(3-hydroxyphenyl)-4-aza-4-methyl-5 $\alpha$ -androst-1-en-3-one;  
17 $\beta$ -(3,4-dihydroxyphenyl)-4-aza-4-methyl-5 $\alpha$ -androst-1-en-3-one;  
15 17 $\beta$ -(3,5-dimethyl-4-hydroxyphenyl)-4-aza-4-methyl-5 $\alpha$ -androst-1-en-3-one;  
17 $\beta$ -(4-hydroxymethylphenyl)-4-aza-4-methyl-5 $\alpha$ -androst-1-en-3-one;  
17 $\beta$ -(2-hydroxyethylphenylcarbonyl)-4-aza-4-methyl-5 $\alpha$ -androst-1-en-3-one;  
20 17 $\beta$ -(4-methoxyphenyl)-4-aza-4-methyl-5 $\alpha$ -androst-1-en-3-one;  
17 $\beta$ -(4-carboxymethylphenyl)-4-aza-4-methyl-5 $\alpha$ -androst-1-en-3-one;  
25 17 $\beta$ -(4-carboxyphenyl)-4-aza-5 $\alpha$ -androst-1-en-3-one;

and the corresponding compounds wherein the  
4-hydrogen substituent is replaced in each of the  
30 above named compounds by a methyl or an ethyl radical.

Also included within the scope of the  
compounds of this invention are those having  
pharmaceutically acceptable salts or esters, where a  
basic or acidic group is present on the adamantlyl or  
norbornanyl moiety. When an acidic substituent is

-7-


present, i.e. -COOH, ammonium, sodium, potassium, calcium salt, and the like, can be formed for use of these compounds in dosage form.

5 Where a basic group is present, i.e. amino, these acidic salts, i.e. hydrochloride, hydrobromide, acetate, pamoate, and the like, can also be used in dosage form.

10 When the -COOH group is present, pharmaceutically-acceptable esters can be employed, e.g. acetate, maleate, pivaloyloxymethyl, and the like, and those esters known in the art for modifying solubility or hydrolysis characteristics.

15 The compounds of formula I of the present invention are prepared by a method starting with the known steroid ester of the formula:

20



25

17β-(carbomethoxy)-4-aza-5α-androstan-3-one

30 which includes the stages of (1) dehydrogenating said starting material to produce the corresponding compound containing a double bond in the 1,2-position

-8-

of the A-ring, (2) converting the 17-carbomethoxy substituent into a 17 $\beta$ -acyl substituent and, if desired (3) alkylating the A-ring nitrogen to introduce 4-methyl or 4-ethyl substituents into the A-ring. For the dehydrogenation step, it is preferable that the 4-aza nitrogen be unsubstituted. The dehydrogenation step can be carried out, e.g. according to the procedure of Dolling, et al. involving dichlorodicyanobenzoquinone, JACS (1988), Vol. 110, pp. 3318-3319. Stage (2) may consist of one or more chemical steps and, if desired, may take place before stage (1) or following stage (1) or stage (3).

In accordance with the process of the present invention, the compounds of this invention are formed by (1) heating a 17 $\beta$ -alkoxycarbonyl-4-aza-5 $\alpha$ -androstan-3-one compound III with a dehydrogenating agent such as benzeneseleninic anhydride in refluxing chlorobenzene to form a 17 $\beta$ -alkoxycarbonyl-4-aza-5 $\alpha$ -androst-1-en-3-one (IV), (2) the formed 5 $\alpha$ -androst-1-en-3-one compound from step (1) is reacted with sodium hydride and under anhydrous conditions in a neutral solvent such as dimethylformamide, (2) contacting the resulting reaction mixture with an alkyl (methyl or ethyl) iodide to form the corresponding 17 $\beta$ -alkoxycarbonyl-4-alkyl-4-aza-5 $\alpha$ -androst-1-en-3-one (V), (3) subsequently hydrolyzing said 17 $\beta$ -alkoxycarbonyl-4-alkyl-4-aza-5 $\alpha$ -androst-1-en-3-one with a strong base such as aqueous methanolic potassium hydroxide at the reflux temperature, followed by acidification and isolation of the resulting steroid acid, 17 $\beta$ -carboxy-4-alkyl-4-aza-5 $\alpha$ -androst-1-en-3-one (VI),

-9-

(4) said steroidal acid is then converted to its corresponding 2-thiopyridyl ester by refluxing with triphenyl phosphine and 2,2'-dipyridyl disulfide in an inert solvent and the product 17 $\beta$ -(2-pyridyl-thiocarbonyl)-4-alkyl-4-aza-5 $\alpha$ -androst-1-en-3-one (VII) is isolated by chromatography on silica, (5) said pyridylthio ester is then reacted with an R<sup>2</sup>-Li or an R<sup>2</sup>MgX (X=Cl, Br) Grignard reagent such as p-methoxyphenyl-magnesium chloride in tetrahydrofuran to form the desired product, e.g. 17 $\beta$ -(p-methoxy-phenylcarbonyl)-4-alkyl-4-aza-5 $\alpha$ - androst-1-en-3-one (VIII) which is isolated by chromatography on silica gel. When this reaction is carried out using an R<sup>2</sup>MgX or, an R<sup>2</sup>-Li compound in place of p-methoxy-phenylmagnesium chloride, the corresponding 17 $\beta$ -(substituted benzoyl)-4-alkyl-4-aza-5 $\alpha$ -androst-1-en-3-one is prepared wherein phenyl is R<sup>2</sup>.

The Grignard reagent, R<sup>2</sup>MgX, for all of the compound species included within the scope of this invention, are available and can be readily made by one skilled in the art.

For example, where R<sup>2</sup> is hydroxyphenyl, this can be derived by starting with an appropriate bromophenol, e.g. p-bromophenol, protecting the phenolic -OH with a conventional blocking group, e.g. triorganosilyl, i.e. t-butyldimethylsilyl, carrying out the Grignard reaction and then deblocking the silyl group by the use of, e.g. refluxing aqueous tetrabutylammonium fluoride.

Where R<sup>2</sup> is hydroxyethylphenyl, the same blocking procedure can be analogously conducted

-10-

starting with the appropriate hydroxyalkyl bromophenol, e.g. p-hydroxymethylbromobenzene, or p-hydroxyethylbromobenzene.

5 Where  $R^2$  is carboxyphenyl, this can be obtained by the chromic acid oxidation of the appropriate hydroxymethylbenzene, e.g. p-bromo-hydroxymethylbenzene, formed as described above.

10 Where  $R^2$  is  $-O-C_1-C_4$  alkyl, the appropriate bromo- $O-C_1-C_4$  alkyl benzene, e.g. p-methoxybromo-benzene, is utilized for the Grignard reaction.

Other halo substituted benzenes to form the appropriate Grignard reagent useful in the instant invention will be obvious to one skilled in the art.

15 By the term "protected hydroxy" as used herein, is meant the alcoholic or carboxylic  $-OH$  groups which can be protected by conventional blocking groups in the art as described in "Protective Groups In Organic Synthesis" by Theodora W. Greene, Wiley-Interscience, 1981, New York. Preferred are the triorganosilyl groups, e.g. t-butyl-dimethylsilyl, phenyldimethylsilyl, diphenylmethylsilyl, and the like.

20 By the term " $C_1-C_4$  alkyl" as used herein, is meant linear or branched alkyl, including methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl and t-butyl.

25 In accordance with the process of the invention, the corresponding  $17\beta$ -benzoyl-4-aza-5 $\alpha$ -androstan-1-en-3-one XV is readily prepared from the 30  $17\beta$ (alkoxycarbonyl)-4-aza-5 $\alpha$ -androst-3-one (IV) by

-11-

repeating the above series of reaction steps but omitting step 2 hereinabove, i.e., treatment of the 4-aza-5 $\alpha$ -androst-1-en-3-one with sodium amide followed by methyl or ethyl iodide.

5        In a further, alternate process, of preparing the compounds of the invention where hydrogen is the sole substituent on the ring A-nitrogen, the double bond in the A-ring is introduced as the last step of the process. Thus, a 10      17 $\beta$ -alkoxycarbonyl-4-aza-5 $\alpha$ -androstan-3-one (III) is hydrolyzed to the corresponding steroidal acid, 17 $\beta$ -carboxy-4-aza-5 $\alpha$ -androstan-3-one, (IX) which, in turn, is converted to the corresponding thio-pyridyl ester,


15      17 $\beta$ -(2-pyridylthiocarbonyl)-4-aza-5 $\alpha$ -androstan-1-one (X) followed by treatment of the ester with an R $^2$ MgX or R $^2$ Li compound wherein R $^2$  is as defined hereinabove to form a 17 $\beta$ -(substituted benzoyl)-4-aza-5 $\alpha$ -androstan-3-one (XI) which is 20      dehydrogenated as previously described to produce compound XIV, 17 $\beta$ -(acyl)-4-aza-5 $\alpha$ -androst-1-en-3-one.

The above reactions are schematically represented in the following structural outline:

25

30

-12-



-13-


wherein X is a 2-pyridylthiocarbonyl substituent and R<sup>2</sup> is defined as hereinabove.

The compounds of the present invention, prepared in accordance with the method described above, are, as already described, potent antiandrogens by virtue of their ability to specifically inhibit testosterone-5 $\alpha$ -reductase.

Also within the scope of the present invention are the ketone reduction products of I, i.e., the secondary alcohols of the formula:

15

20



wherein R is selected from hydrogen, methyl and ethyl, and R<sup>2</sup> is phenyl substituted with one or more of -OH, -OC<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkyl, -(CH<sub>2</sub>)<sub>m</sub>OH, -(CH<sub>2</sub>)<sub>n</sub>COOH, including protected hydroxy, where

30

-14-

5

$m$  is 1-4,  $n$  is 1-3, providing  $C_1-C_4$  alkyl is only present when one of the above oxygen-containing radicals is present, wherein the dotted line represents a double bond which can be present, and pharmaceutically acceptable salts and esters thereof.

10

15

These compounds can be made by conventional sodium borohydride reduction of the carbonyl attached to  $R^2$  without reducing the amide carbonyl in Ring A or the 1,2-double bond, if present. If the  $R^2$  phenyl contains a carbonyl function, it can be selectively blocked and then regenerated after the borohydride reduction by conventional methods.

20

The borohydride reduction can be carried out in, e.g. water or aqueous methanol, at a temperature of from about room temperature to about 50°C and the product then isolated and purified by conventional means. The compounds are also active as 5-alpha reductase inhibitors.

25

30

Compositions containing the compounds of the present invention as the active ingredient for use in the treatment of baldness can be administered in a wide variety of therapeutic dosage forms in conventional vehicles for systemic administration, as, for example, by oral administration in the form of tablets, capsules, solutions, or suspensions, or by topical administration in an appropriate vehicle. The daily dosage of the products may be varied over a wide range varying from 0.1 to 2,000 mg.

An effective amount of the drug is ordinarily supplied at a dosage level of from about 0.01 mg. to about 50 mg./kg. of body weight per day.

-15-

Preferably the range is from about 0.1 mg. to 7 mg./kgs. of body weight per day. These dosages are well below the toxic dose of the product. Capsules containing the product of this invention can be 5 prepared by mixing an active compound of the present invention with lactose and magnesium stearate, calcium stearate, starch, talc, or other carriers, and placing the mixture in gelatin capsule. This, or a similar mixture can be prepared in the form of 10 discrete particles which can also be placed in gelatin capsules to provide slow release formulations.

Tablets may be prepared by mixing the active ingredient with conventional tabletting ingredients such as calcium phosphate, lactose, corn starch or 15 magnesium stearate. The liquid forms in suitably flavored suspending or dispersing agents such as the synthetic and natural gums, for example, tragacanth, acacia, methyl-cellulose and the like. Other dispersing agents which may be employed include 20 glycerin and the like. For parenteral administration, sterile suspensions and solutions are desired.

For the treatment of baldness, the compounds of the present invention are administered in pharmaceutical compositions containing the active 25 invention compound in combination with a pharmacologically acceptable carrier adapted for topical administration. These topical pharmaceutical compositions may be in the form of a cream, ointment, gel or aerosol formulation adapted for application to 30 the skin. Topical pharmaceutical compositions containing the compounds of the present invention typically include about 0.1% to 15%, preferably about 5%, by weight of the active compound in admixture with a suitable vehicle.

-16-

Methods for preparing the 17 $\beta$ -N-mono-substituted or 17 $\beta$  acyl carbamoyl compounds of the present invention are illustrated by the following examples.

5

General Procedure for Preparing Protected Silyl Derivatives

1.0 mole of phenol or its derivatives, or 1 mole of alcohol is treated with 1.5 liters of dry 10 methylene chloride. To the clear solution is added dry 3.0 moles of imidazole/N<sub>2</sub>. The clear solution is cooled to 0°C/N<sub>2</sub>, and 2.0 moles of t-butyl dimethyl chlorosilane in 300.0 ml of dry methylene chloride is added dropwise at 0°C/N<sub>2</sub>. Towards the end of the 15 addition, precipitation occurs. The ice bath is removed, and the reaction is allowed to proceed overnight at R.T./N<sub>2</sub>. Filter, wash the cake with cold CH<sub>2</sub>Cl<sub>2</sub> solution, and the solvent is evaporated in vacuo to afford crude product. The crude product 20 was readily purified by filtering through a silica gel column. (1 gr. of crude product per 100 g of silica gel, using CH<sub>2</sub>Cl<sub>2</sub> as eluant) This method gives about 99% of pure silyl derivatives for phenols and alcohols.

25

EXAMPLE 1

Methyl 3-oxo-4-aza-5 $\alpha$ -androst-1-ene-17 $\beta$ -carboxylate

A suspension of 83.7 g of methyl 3-oxo-4-aza-5 $\alpha$ -androstane-17-carboxylate\* and 126.5 g of 30 benzeneseleninic anhydride in 2.09 l of chlorobenzene was heated at reflux for 2 hours. The reflux condenser was switched to a distillation head and the mixture was distilled slowly to remove water that had formed in the reaction (2 hours). The solution was

-17-

evaporated to leave 198 g of wet residue. The residue as a solution in dichloromethane was washed with saturated aqueous  $\text{NaHCO}_3$  solution and saturated  $\text{NaCl}$  solution, then dried and evaporated to leave 172.4  
5 g. This material was chromatographed on 2.56 kg of silica gel eluting first with dichloromethane (5 liters) and then with 4:1 dichloromethane acetone. The desired product was eluted with 8 liters of the above-mixed solvent and evaporated in vacuo to yield  
10 53.4 g. It was washed with diethyl ether and dried to leave 49.5 g of the above-titled product, m.p.  
278-280°C.

\* See Rasmusson, Johnston and Arth. U.S. Patent  
15 4,377,584, March 22, 1983.

EXAMPLE 2

S-(2-Pyridyl)-3-oxo-4-aza-5 $\alpha$ -androst-1-ene-17 $\beta$ -thiocarboxylate

20 A suspension of 25.0 g of the above product from Example 1 was saponified with 12.5 g of KOH in 150.0 ml of 5:1  $\text{CH}_3\text{OH}-\text{H}_2\text{O}$  under reflux conditions for 4 hours/ $\text{N}_2$ . The mixture was cooled to 25°C and acidified to pH <2. Water (175 ml) was added gradually  
25 with stirring to leave a crystalline precipitate which was collected and washed with water.

After drying, the product amounted to 25 g., m.pt 313-315°C with decomposition.

30 The crude dry acid (23.0 g) was suspended in 210 ml of toluene, and to the suspension was added triphenylphosphine (56.0 g) and 2,2'-dipyridyl disulfide (48.3g), and the mixture was stirred at 24°C overnight/ $\text{N}_2$ . The reaction mixture was placed on a column of silica gel (1.3 kg) and was eluted

-18-

with 1:1 (acetone/CH<sub>2</sub>Cl<sub>2</sub>). The desired thioester eluted slowly, and after rinsing with ether, yielded 36.8 g of the above-titled product, m.p. 232-235°C.

5

EXAMPLE 3

Synthesis of 17- $\beta$ -(4-Hydroxybenzoyl)-4-aza-5- $\alpha$ -androst-1-ene-3-one

---

A. Preparation of Grignard Reagent

10 To a suspension of 1.22 g of dry activated magnesium chips in 20.0 ml of dry THF was added 5.6 g of 1-bromo-4-tertiary-butyl dimethyl silyloxybenzene (prepared from p-bromophenol by the General Procedure detailed above) in 10.0 ml of THF under N<sub>2</sub>. The 15 reaction was run in an ultrasonic bath at a temperature range of 24-30°C. To the well-agitated mixture was added dropwise 150  $\mu$ l-200  $\mu$ l of 1,2-dibromoethane/N<sub>2</sub>. The reaction was allowed to proceed for 1-1 1/2 hours at 28°C/N<sub>2</sub>. The concentration of the Grignard reagent formed was 19.5 20 mmoles in 30.0 ml of dry THF.

25 The steroid from Example 2 (1.02 g, 2.49 mmoles) was suspended in 20.0 ml of dry THF, cooled to -80°C and the above-prepared Grignard (11.5 ml; 3 equivalents) was added via syringe to the steroidal suspension in 5-10 minutes/N<sub>2</sub>. The reaction was allowed to proceed for 1 hour at -80°C/N<sub>2</sub>, and then at -10°C for an additional hour/N<sub>2</sub>. The reaction solution was diluted with 10.0 ml of methylene 30 chloride and quenched with a saturated aqueous solution of NH<sub>4</sub>Cl to pH=4. Organic layers were separated, washed 3 times with H<sub>2</sub>O, 3 times with saturated sodium chloride, dried over MgSO<sub>4</sub>,

-19-

filtered, and evaporated under a vacuum to a yellow color solid. Crystallization from ethyl acetate afforded 607 mg of product m.p. 248-249°C.

Anal. Calcd. for  $C_{31}H_{45}O_3NSi$ :

5 C, 73.32; H, 8.93; N, 2.75

Found: C, 73.27; H, 8.99; N, 2.75.

FAB: Found 508; Calc. 508.

B. Desilylation

10 Dissolved 1.3g of product from above step A in 20.0 ml of dry THF. Cooled to -5°C and added 437 µl of glacial acetic acid/N<sub>2</sub>. To the cold solution at -5°C was added via syringe 3.0 ml tetra-n-butyl-ammonium fluoride dropwise under N<sub>2</sub> atmosphere. The 15 reaction was allowed to proceed under stirring for 1 1/2-2 hours at 0° to -5°C/N<sub>2</sub>. The reaction mixture was poured into a 2-layer mixture of ethyl acetate/sodium bicarbonate saturated solution at 0°C. The water layer was separated and further 20 extracted with EtOAc 3 times and with CH<sub>2</sub>Cl<sub>2</sub> (3 times).

The organic layers were combined, washed 3 times with H<sub>2</sub>O, 1 time with saturated sodium chloride solution, and dried over MgSO<sub>4</sub>, filtered and 25 evaporated to dryness under vacuum. The crude product was crystallized from ethyl acetate to afford 977.9 mg, and further recrystallized from methanol to afford 842.3 mg of the above-titled product, m.pt. 296-297°C.

30 Anal. Calcd. for  $C_{25}H_{31}NO_3.1/3 H_2O$ :  
C, 75.15; H, 7.98; N, 3.51.

Found: C, 75.13; H, 7.76; N, 3.54.

(Mass Spec.) FAB: Found 394; Calcd. 394.

-20-

EXAMPLE 4

17- $\beta$ -(3,5-dimethyl-4-hydroxybenzoyl)-4-aza-5 $\alpha$ -androst

-

1-ene-3-one

---

5

A. Preparation of Grignard Reagent

To a suspension of 260.0 mg of dry activated magnesium chips in 6.0 ml of dry THF was added 628.0 mg of 1-bromo-3,5-dimethyl-4-tertiary-butyl-dimethyl-10 silyloxybenzene (prepared from 4-bromo-2,6-dimethylphenol by the General Procedure described above) in 4.0 ml of THF/N<sub>2</sub>. The reaction was conducted in an ultrasonic bath at a temperature range of 24°-30°C. To the well-agitated mixture was added dropwise 40  $\mu$ l of 1,2-dibromoethane/N<sub>2</sub>. The reaction was allowed to proceed for 2 hours/N<sub>2</sub>. The concentration of the Grignard reagent thus formed was 2 mmoles in 10.0 ml of dry THF.

20 The steroid from Example 2 (205.0 mg (0.5 mmoles) was suspended in 3.0 ml of dry THF, cooled to -80°C, and 7.5 ml of the above-prepared Grignard was introduced via syringe to the steroidal suspension over a period of 5-10 minutes/N<sub>2</sub>. The reaction was allowed to proceed for 1 hour at -80°C/N<sub>2</sub> and then at 25 -10°C for additional hour/N<sub>2</sub>.

30 The reaction was quenched with 1N HCl, and then diluted with chloroform. The organic layers were combined, washed 3 times with H<sub>2</sub>O, 3 times with saturated sodium chloride and dried over MgSO<sub>4</sub>, filtered and concentrated in vacuo. The crude residue was washed with ether to afford 121.7 mg of product.

The crude product was dissolved in 70:30 (CHCl<sub>3</sub>-acetone), filtered through Teflon (Acrodisc CR) and purified by preparative HPLC (Waters Prep-pak) on silica gel and eluted with 70:30 (CHCl<sub>3</sub>-acetone).

-21-

The major component was recrystallized from ethyl acetate to give 52.0 mg of product m.pt 245-245.5°C.

Anal. Calcd. for  $C_{33}H_{49}O_3NSi$ :

5 C, 73.96; H, 9.23; N, 2.61

Found: C, 74.06; H, 9.33; N, 2.64

(Mass Spec.) FAB: Found: 536; Calc.: 536

B. Deblocking the Silyl Derivative

10 Dissolved 54.0 mg of the above product from A in dry THF (1.3 ml). The clear solution was cooled to 0°C, and 29  $\mu$ l of glacial HOAc was added via syringe/ $N_2$ . To the above solution was added dropwise 172  $\mu$ l of tetra-n-butylammonium fluoride at 0°C  
15 dropwise via syringe/ $N_2$ . Allowed the reaction to proceed at 0°C/ $N_2$  for 1 1/2 hours. The reaction mixture was poured into ice/saturated  $NaHCO_3$  solution and EtOAc. Stirred for several minutes. Allow the layers to separate, and the  $H_2O$  layer was  
20 extracted 3 times with EtOAc and 3 times with  $CHCl_3$ .

Combined the organic layers and washed 3 times with  $H_2O$ , then 3 times with saturated  $NaCl$ , and then dried over  $MgSO_4$ , filtered and evaporated to dryness in vacuum to afford 52.2 mg.

25 The product was crystallized from EtOAc to give 22.5 mg of the above-titled product m.pt 305-306°C.

Calc. for  $C_{27}H_{35}O_3N$

(Mass Spec.) FAB: Calc: 422; Found: 422

-22-

EXAMPLE 5

Synthesis of 17- $\beta$ -(4-Methoxybenzoyl)-4-aza-5- $\alpha$ -androst-1-ene-3-one

5      A. Preparation of Grignard Reagent

To a suspension of 258.0 mg of dry activated Mg chips in 8.0 ml of THF/N<sub>2</sub> was added 748.0 mg p-bromoanisole in 2.0 ml of dry THF. The reaction was run in an ultrasonic bath at a temperature range of 24-30°C/N<sub>2</sub>. To the well-agitated mixture was added dropwise 30.0  $\mu$ l of 1,2-dibromoethane as a catalyst. The reaction was allowed to progress for 1-2 hours at 28°C. The formed Grignard reagent had a concentration of 4 mmoles in 10.0  $\mu$ l of dry THF.

15      The steroid from Example 2 (205.0 mg (0.50 mmol) was suspended in 2.0 ml of THF, cooled to -78°C and the above-prepared Grignard reagent (3.75 ml; 3 equivalents) was added via syringe to the steroidal suspension over 5-10 minutes/N<sub>2</sub> and then at -10°C for an additional hour/N<sub>2</sub>. The resulting reaction mixture was a clear solution, which was cooled to 0-5°C, diluted with chloroform and quenched with 1N HCl acid. The organic layers were separated, washed with H<sub>2</sub>O 2 times, followed with saturated NaCl solution, dried over MgSO<sub>4</sub>, filtered and evaporated in vacuo. The crude product was washed with ether, and crystallized from EtOAc to give 110 mg of product m.pt 305-306°C.

20      Further purification was carried out by chromatographic isolation on a TLC plate, (20 cm x 20 cm x 1000  $\mu$ m), using as eluant, 70:30 (CHCl<sub>3</sub>: acetone). Recrystallization from EtOAc yielded 78.56 mg of the above-titled product, m.pt 305-306°C (dec.).

25      (Mass Spec) FAB: Calcd., 408; Found 408.

-23-

EXAMPLE 6

Synthesis of 17- $\beta$ -(3-hydroxybenzoyl)-4-aza-5 $\alpha$ -  
androst-1-ene-3 one

---

5      A. Preparation of Grignard Reagent

To a suspension of 230.0 mg of dry activated Mg chips in 2.0 ml of dry THF was added 722.5 mg of 1-bromo-3-tertiary-butyl dimethyl-silyloxybenzene (prepared from 3-bromophenol by the General Procedure described above) in 8.0 ml of dry THF/N<sub>2</sub>. The reaction was run in an ultrasonic bath at a temperature range of 24-30°C/N<sub>2</sub>. To the well-agitated mixture was added dropwise 20.0  $\mu$ l of 1,2-dibromoethane/N<sub>2</sub>. Allowed the reaction to progress for 2 1/2 hours at 28°C/N<sub>2</sub>. The formed Grignard reagent had a concentration of 2.52 mmoles in 10.0 ml of dry THF.

20      The steroid from Example 2 (205.0 mg (0.5 mmoles) was suspended in 2.0 ml of THF, cooled to -78°C and the above-prepared Grignard reagent (6.0 ml (3 equivalents)) was added via syringe to the steroidal suspension over 5-10 minutes/N<sub>2</sub>, and then stirred for an additional hour at -10°C/N<sub>2</sub>. The clear reaction mixture was quenched at 0 to -5°C with 1N HCl acid for 10.0 minutes and diluted with CHCl<sub>3</sub>. The combined organic layers were washed 3 times with H<sub>2</sub>O, 3 times with saturated NaCl, and then dried over MgSO<sub>4</sub>, filtered and concentrated in vacuo to afford crude product. The product was purified on silica gel column and was eluted with 70:30 (CHCl<sub>3</sub>-acetone). The desired product amounted to 58.0 mg, as the silyl derivative, 17 $\beta$ -(3-tertiary-butyl-dimethylsilyloxybenzoyl)-4-methyl-4-aza-5 $\alpha$ -androst-1-en-3-one.

-24-

B. Deblocking

5 57.6 mg of the above silyl derivative was dissolved in 3.0 ml of dry THF. The solution was cooled to 0°C, and 20 µl of glacial acetic acid was introduced via syringe. To the clear solution was added 130.0 µl of (n-butyl)<sub>4</sub>NF via syringe, and allowed the reaction to proceed for 1 hour/N<sub>2</sub> at 0°C. The water layer was separated, extracted 3 times with EtOAc and then 3 times with chloroform.

10 The organic layers were combined and washed 3 times with H<sub>2</sub>O, 3 times with saturated NaCl solution, dried over MgSO<sub>4</sub>, filtered and evaporated in vacuo to give 57.11 mg of crude product. The crude product was chromatographed by TLC (one plate, 20 cm x 20 cm x 15 250 µm silica gel), eluted with 70:30 (CHCl<sub>3</sub>-acetone) to afford 44.5 mg of the above-titled product. Recrystallization from EtOAc gave 29.30 mg m.pt 279-280°C.

Anal. Calcd. for C<sub>25</sub>H<sub>31</sub>NO<sub>3</sub>: 8H<sub>2</sub>O:  
20 C, 73.60; H, 8.06; N, 3.43.  
Found: C, 73.26; H, 8.22; N, 3.28.  
(Mass Spec.) FAB: Calcd: 394; Found 394.

EXAMPLE 7

25 Synthesis of 17-β-(4-hydroxymethyl-benzoyl)-4-aza-5α-androst-1-en-3-one

A. Preparation of Grignard solution

30 To a suspension of 100.0 mg (4 mmoles) of dry activated Mg chips in 5.0 ml of dry THF/N<sub>2</sub>, was added 753.0 mg (2.5 mmoles) of 1-bromo-4-tertiary-butyl dimethyl silyloxy methyl benzene (prepared from 4-bromobenzyl alcohol by the General Procedure described above). The reaction was con-

-25-

ducted in an ultrasonic bath at a temperature range of 24-30°C/N<sub>2</sub>. To the well-agitated mixture was added 20  $\mu$ l of 1,2-dibromoethane/N<sub>2</sub>. Allowed the reaction to progress for 2 hours at 28°C/N<sub>2</sub>. The 5 concentration of formed Grignard was 2.5 mmoles in 5.0 ml of dry THF.

**B. Grignard Reaction**

10 The steroid from Example 2 (205.0 mg (0.5 mmoles) was suspended in 2.0 ml of THF, cooled to -78°C, and the above-prepared Grignard (3.0 ml, 3 equivalents) was introduced via syringe into the steroidal suspension over 5-10 minutes/N<sub>2</sub>. Allowed the reaction to progress for 1 hour at -80°C/N<sub>2</sub>, and then for an additional hour at -10°C/N<sub>2</sub>. The clear 15 reaction solution was quenched with saturated NH<sub>4</sub>Cl at 0° to -5°C, and then diluted with CH<sub>2</sub>Cl<sub>2</sub>. The organic layers were separated and washed 3 times with water, 3 times with saturated NaCl, dried over MgSO<sub>4</sub>, filtered and evaporated in vacuo to dryness. Crude 20 product was crystallized from EtOAc to give 137.8 mg of silyl product.

(Mass Spec.) FAB: Calcd.: 522; Found: 522.0.

25 **C. Deblocking of Silyl Derivative**

The product from Step B above (23.67 mg) was dissolved in 0.5 ml of THF and 0.5 ml of MeOH and cooled to 0°C/N<sub>2</sub>. To the cold solution was added 10  $\mu$ l of concentrated sulfuric acid (98%). The reaction 30 was stirred for 45 minutes at 0°C/N<sub>2</sub>. To the cold solution at 0°C was slowly added a saturated solution of NaHCO<sub>3</sub> (3 times). The organic layer was collected and washed 3 times with water, 3 times with saturated solution of NaCl, dried over MgSO<sub>4</sub>, filtered and evaporated to dryness in vacuo, to afford

-26-

10.18 mg. The crude product was crystallized from EtOAc to give 6.0 mg of the above-titled product, m.pt 318-320°C.

5           Anal. Calcd. for  $C_{26}H_{33}O_3N \cdot 1/3H_2O$ :  
                 C, 75.41; H, 7.94; N, 3.38.  
          Found: C, 75.61; H, 7.84; N, 3.12.  
          (Mass Spec.) FAB: Calc.: 408; Found: 408

10

EXAMPLE 8

Synthesis of 17- $\beta$ -(4-Carboxybenzoyl)-4-aza-5 $\alpha$ -androst-1-en-3-one

A. Oxidation

15           90.2 mg of the product from Example 7 was dissolved in 2.63 ml of glacial acetic acid and to the clear solution was added 69.0 mg of CrO<sub>3</sub> (previously dried over P<sub>2</sub>O<sub>5</sub> at R.T. for 2 days in vacuo). After stirring overnight, the reaction mixture was diluted with water and allowed to age overnight in the refrigerator. The reaction mixture was filtered and the mother liquor and washes were extracted overnight using a water-EtOAc extractor, under reflux conditions. The organic layer was dried 20           over MgSO<sub>4</sub>, filtered and evaporated in vacuo. The residue was dissolved in hot MeOH, filtered and 25           evaporated in vacuo to afford a product weighing 32.0 mg.

30           FAB: (Calc. for  $C_{26}H_{31}O_4N$ : 422.0;  
                  Found: 422.

B. Purification

The above free acid was purified by dissolving the above product in 1N sodium hydroxide solution. The clear solution was extracted 3 times with EtOAc. The aqueous basic solution was cooled

-27-

and acidified with 1N HCl acid dropwise to pH=4 with stirring. The reaction mixture was allowed to age for 1 hour at 0°C. It was filtered and the residue was washed with cold water. Dried overnight to 100°C in vacuum <0.2 mm pressure.

5 Yield of the above-titled free acid was 9.85 mg. FAB: Calc. for C<sub>25</sub>H<sub>31</sub>O<sub>4</sub>N: 422; Found 422. NMR analysis indicated the product to be an acid.

10 C. Sodium Salt of Above Acid

4.9 mg of the above product acid B was dissolved in 2.0 ml of hot methanol. To the clear solution, was added 11.6  $\mu$ l of 1N NaOH(aq). The solution was evaporated in vacuo nearly to dryness, addition 2.0 ml of water was added to reach pH 7.21. The aqueous solution was freeze dried to give 6.3 mg of the sodium salt of the above-titled product.

EXAMPLE 9

20 Synthesis of 17- $\beta$ -(4-hydroxyethylbenzoyl)-4-aza-  
5 $\alpha$ -androst-1-en-3-one

A. Grignard Reagent

To a suspension of 252 mg of dry activated Mg chips in 10.0 ml of dry THF was added 1.26 g (4 mmoles) of 1-bromo-4 tertiary-butyl dimethyl silyloxy ethyl benzene (prepared from 2-(p-bromophenyl) ethanol by the General Procedure described above). The reaction mixture was vigorously stirred using an ultrasonic vibrator/N<sub>2</sub>. To the well-agitated mixture was added 40  $\mu$ l of 1,2-dibromoethane to catalyze the above reaction. Allowed the reaction to progress for 3 1/2-4 hours/N<sub>2</sub>. The concentration of formed

-28-

Grignard reagent was 4 mmoles in 10 ml of THF.

B. Grignard Reaction

205.0 mg (0.5 mmoles) of the aza-steroid of  
5 Example 2 was suspended in 2.0 ml of dry THF/N<sub>2</sub>,  
cooled to -80°C, and the above-prepared Grignard  
(3.75 ml was added 3 equivalents) via syringe was  
introduced into the steroidal suspension over 5-10  
10 minutes/N<sub>2</sub>. The reaction was run at -80°C for 1  
hour/N<sub>2</sub> and then for an additional hour at -10°C.  
The reaction was quenched with a saturated solution  
of NH<sub>4</sub>Cl at 0-5°C and diluted with 10.0 ml of  
CH<sub>2</sub>Cl<sub>2</sub>. The organic layers were washed with water (3  
15 times), saturated NaCl solution (3 times), dried with  
MgSO<sub>4</sub>, filtered and evaporated in vacuo to dryness.  
The crude product was crystallized from EtOAc  
overnight to give 152.0 mg of product m.pt. 233-234°C.

Anal. Calcd. for C<sub>33</sub>H<sub>49</sub>O<sub>3</sub>NSi: 1/4 H<sub>2</sub>O:  
C, 73.55; H, 9.18; N, 2.59.

20 Found: C, 73.45; H, 8.94; N, 3.21

FAB: Calc. 536; Found: 536

C. Desilylation

70.8 mg of product from Step B, was  
25 dissolved in 1.45 ml of methanol and 1.45 ml of THF.  
The solution was cooled to 0-5°C and 29 µl of conc.  
H<sub>2</sub>SO<sub>4</sub> was added via syringe under N<sub>2</sub>. The reaction  
was allowed to proceed for 45 minutes/N<sub>2</sub>. The  
reaction was carefully quenched at 0°C with a  
30 saturated solution of NaHCO<sub>3</sub>, and extracted 3 times  
with CH<sub>2</sub>Cl<sub>2</sub>. The organic layers were separated,  
washed with water (3 times), then with saturated NaCl

-29-

solution, dried over  $MgSO_4$ , filtered and evaporated in vacuo to give 43.0 mg of crude product. The crude product was placed on a column of silica gel and was eluted with 1:1 (acetone- $CH_2Cl_2$ ). The isolated 5 product was crystallized from anhydrous methanol to afford 20.0 mg of the above-titled product m.pt 292-293°C with dec.

Anal. Calcd. for  $C_{27}H_{35}O_3N \cdot 1/4 H_2$ :  
C, 75.31; H, 3.25; N, 3.25.  
10 Found: C, 75.49; H, 3.45; N, 3.45.  
FAB: Calcd 422; Found 422.

#### EXAMPLE 10

15 Synthesis of 17- $\beta$ -(4-carboxymethylbenzoyl)-4-aza-5 $\alpha$ -androst-1-en-3-one

---

A. Oxidation

20 13.0 mg of the product from Example 9 was dissolved in 1 ml of glacial acetic acid. To the clear solution was added 10.0 mg of  $CrO_3$  (previously dried over  $P_2O_5$  in vacuum at R.T.). Allowed the reaction to progress overnight at R.T., and then at 0°C for 48 hours. The addition of 7.0 ml of water caused the product to crystallize overnight in a 25 refrigerator. The crude product was isolated, washed with cold water and dried in a vacuum at 110°C below 1 mm pressure.

30 The dried crude product was dissolved in 1N sodium hydroxide and the basic solution was extracted 3 times with methylene chloride (The organic layers were separated, and the aqueous basic solution was cooled and acidified with 1.5 N hydrochloric acid. The precipitate was filtered, washed with water dried at 110°C under vacuum at 0.1 mm pressure.

-30-

Yield of above-titled product=7.0 mg.

FAB Calc. C<sub>27</sub>H<sub>33</sub>O<sub>4</sub>N: 436; Found 436.

EXAMPLE 11

5      Synthesis of 17- $\beta$ -(3,4-dihydroxybenzoyl)-4-aza-5 $\alpha$ -androst-1-en-3-one

---

A. Grignard

10      To a suspension of 285 mg of dry activated magnesium chips in 10.0 ml of dry THF, was added 428  $\mu$ l of 4-bromo-1,2-methylenedioxybenzene/N<sub>2</sub>. (The starting material is commercially available from Aldrich Chemical) The reaction was conducted in an ultrasonic water bath at a temperature range of 24°-30°C. To the well-agitated mixture was added 40  $\mu$ l of 1,2-dibromoethane as a catalyst/N<sub>2</sub>, and the reaction was allowed to progress for 1 1/2-2 hours at 28°C/N<sub>2</sub>. The concentration of the formed Grignard reagent was 3.75 mmoles in 10 ml of dry THF.

20      The steroid from Example 2 (41 mg, 1mmole) was suspended in 4.0 ml of dry THF/N<sub>2</sub> and cooled to -80°C and 8.0 ml of the above-prepared Grignard (3 equivalents) was added via syringe to the steroidal suspension/N<sub>2</sub> over a period of 5-10 minutes. The reaction was allowed to proceed for 1 hour at -80°C, and then at -10°C for an additional hour/N<sub>2</sub>. The reaction mixture was diluted with CH<sub>2</sub>Cl<sub>2</sub>, and then quenched with 1N HCl at -5°C.

30      The organic layers were collected and washed with water 3 times, saturated NaCl solution 3 times, dried over MgSO<sub>4</sub>, filtered and evaporated in vacuo to dryness. Purification of the crude product was

-31-

carried out on 50.0 g of silica gel using as eluant 1:1(CH<sub>2</sub>Cl<sub>2</sub>-acetone) to give 347.0 mg.

FAB showed 422; Calcd. 422.

62.4 mg of the above product was  
5 crystallized from EtOAc to afford 11.39 mg of product  
m.pt.324-325°C.

Anal. Calcd. for C<sub>26</sub>H<sub>31</sub>O<sub>4</sub>N . 3/4 H<sub>2</sub>O:

C,71.78; H,7.53; N,3.22.

Found: C,71.90; H,7.54; N,3.25.

10 FAB for C<sub>26</sub>H<sub>31</sub>O<sub>4</sub>N showed 422; Calcd: 422.

B. Cleavage of Methylene Dioxylan Group

70.0 mg of the product from Step A was dissolved in dry 25.0 ml of 1,2-dichloroethane at  
15 R.T./N<sub>2</sub>. The solution was allowed to cool to -10°C, and 1.03 ml of BBr<sub>3</sub> (1.0 M solution in dichloromethane) was added dropwise under N<sub>2</sub> atmosphere. The reaction was allowed to proceed at R.T. for 3 1/2-4 hours/N<sub>2</sub>. After 4 hours/N<sub>2</sub>, the reaction was cooled to (-10°C) and quenched with 10.0 ml of methanol for 10 minutes at 0°C, and then gradually the temperature was allowed to rise to R.T./N<sub>2</sub>. The reaction mixture was evaporated in vacuo to dryness. The residue was extracted 3 times  
20 with EtOAc. The organic layers were washed with water 3 times, 2 times with saturated NaHCO<sub>3</sub> solution, 3 times with water and finally with a saturated solution of NaCl. The organic layers were dried over magnesium sulfate, filtered and  
25 concentrated in vacuo. The crude material was chromatographed on 2 silica gel plates, (20 cm x 20 cm x 20 cm x 250 µm) eluted with 1:1 (acetone -

-32-

methylene chloride). Recrystallization from EtOAc afforded 5.0 mg of the above-titled product m.p. 222-222.5°C.

Anal. Calcd. for  $C_{25}H_{31}O_4N \cdot 1/2 H_2O$ :

5 C, 71.78; H, 7.66; N, 3.35.

Found: C, 71.71; H, 7.71; N, 3.33.

FAB: Calcd. for  $C_{25}H_{31}O_4N$ : 410; Found 410.

EXAMPLE 13

10 Synthesis of 17- $\beta$ -(2 methoxybenzoyl)-4-aza-5 $\alpha$ -androst-1-ene-3-one

A. Grignard

15 To a suspension of 258.0 mg of dry activated magnesium chips in 8.0 ml of dry THF was added 771.0 mg of o-bromoanisole in 2.0 ml of dry THF/ $N_2$ . The reaction was conducted in an ultrasonic water bath at a temperature range of 24-30°C. To the well-agitated mixture was added 30  $\mu$ l of 1,2-dibromoethane/ $N_2$ , and 20 the reaction was allowed to progress for 2 hours at 28°C/ $N_2$ . The concentration of the formed Grignard reagent was 4 mmoles in 10.0 ml of dry THF.

25 The steroid from Example 2 (205 mg, 0.5 mmoles) was suspended in 2.0 ml of dry THF/ $N_2$ , cooled to -79°C, and 4.0 ml of the above-prepared Grignard (3 equivalents) was added via syringe to the steroidal suspension/ $N_2$  over a period of 5-10 minutes. The reaction mixture was allowed to proceed for 1 hour at -80°C, and then at 0-2°C for an additional hour/ $N_2$ . The reaction mixture was diluted with  $CH_2Cl_2$  and then quenched with 1N HCl solution at 0°C.

-33-

The organic layers were combined, washed 3 times with water, 3 times with saturated NaCl solution; and dried over MgSO<sub>4</sub>. Filtered and evaporated in vacuum to dryness. The crude material was crystallized from EtOAc to give 124.5 mg of product m.pt 228-230°C. Purification on silica gel column using 70:30 (CHCl<sub>3</sub>-acetone) gave a single spot material in a yield of 83.0 mg m.pt. 241-241.5.

Anal. Calcd. for C<sub>26</sub>H<sub>33</sub>O<sub>3</sub>N:

10 C, 76.91; H, 8.19; N, 3.95

Found: C, 76.36; H, 8.26; N, 3.35.

FAB calcd. for C<sub>26</sub>H<sub>33</sub>O<sub>3</sub>: 406; Found: 406.

B. Cleavage of Methoxy Group

15 12.7 mg (0.03 mmoles) of the product from Step A was dissolved in 5.0 ml of dry methylene chloride/N<sub>2</sub>. To clear solution at -79°C/N, was added 50  $\mu$ l of 1 mmole/ml of BBr<sub>3</sub> in CH<sub>2</sub>Cl<sub>2</sub> via syringe dropwise. Allowed the reaction to proceed at R.T. overnight/N<sub>2</sub> with rapid stirring. Next day, a clear yellow solution was obtained. The reaction mixture was cooled to 0-2°C and quenched with water, to hydrolyze excess of BBr<sub>3</sub>. The organic phase was washed 3 times with dilute sodium hydroxide, 3 times with water, 3 times with dilute HCl, 3 times with water, 3 times with saturated NaCl solution, and dried the organic layer over MgSO<sub>4</sub>. Filtered, concentrated in a vacuum to dryness. The crude product crystallized from EtOAc to afford 7.0 mg of a pure single spot material being 17- $\beta$ -(2-hydroxy-methyl-benzoyl)-4-aza-5- $\alpha$ -androst-1-en-3-one.

30 FAB for C<sub>25</sub>H<sub>31</sub>NO<sub>2</sub>; Calcd: 394; Found: 394.

-34-

EXAMPLE 14

17 $\beta$ ( $\alpha$ -hydroxy benzyl)-4-aza-5 $\alpha$ -androst-1-ene-3-one

570 mg of

17 $\beta$ -benzoyl-4-aza-5 $\alpha$ -androst-1-ene-

5 3-one (prepared from the thiopyridyl ester of Example 2 and commercially available phenyl magnesium bromide, 3 equivalents, analogously via the procedure in Example 3, second paragraph, to produce the 17-benzoyl derivative, mp. 295-296°C crystallized from EtOAc) was suspended in 80 ml of anhydrous isopropanol. To the suspension was added 500.0 mg of NaBH<sub>4</sub> in 5 portions. When all the hydride was added, 20.0 ml of dry THF was carefully added, so that the reaction mixture became a clear solution. Allowed 10 the reaction mixture to proceed at R.T./N<sub>2</sub> overnight. The reaction was quenched carefully with 1N HCl, and allowed to stir under N<sub>2</sub> for an additional hour at R.T. It was then diluted with water, and extracted 3 times with CHCl<sub>3</sub>. The organic 15 layers were combined, washed 3 times with H<sub>2</sub>O; 3 times with saturated NaCl solution, and dried over MgSO<sub>4</sub>. Filtered and evaporated to a white solid 20 weighing 575.0 mg.

The crude material was crystallized from 25 EtOAc to afford 390.0 mg of material m.pt. 299-301°C. Further purification on a silica gel column, using as eluant, 70:30 (CHCl<sub>3</sub>-acetone) gave a single spot material, 360.0 mg, of the above-titled compound, m.pt 305-306°C.

30 Anal. Calcd. for C<sub>25</sub>H<sub>33</sub>NO<sub>2</sub>:

C, 79.17; H, 8.78; N, 3.70.

Found: C, 79.24; H, 8.85; N, 3.48.

FAB Calcd. for C<sub>25</sub>H<sub>33</sub>NO<sub>2</sub>: 380; Found: 380.

-35-

EXAMPLE 15

17 $\beta$ -hydroxymethyl-4aza-5 $\alpha$ -androst-1-ene-3-one

500.0 mg of S-2-pyridyl-3-oxo-4aza-5 $\alpha$ -androst-1-ene-3 one (Example 2) was dissolved in 40.0 ml of dry THF at R.T./N<sub>2</sub>. The solution was cooled to -78°C/N<sub>2</sub> and 5.5 ml of 1 M dibutyl aluminium hydride in THF was slowly added via syringe to the solution, with rapid stirring. Allowed the reaction to proceed at -76 to -78°C for half an hour under N<sub>2</sub>. The 10 temperature was gradually brought to R.T. and the reaction mixture kept for 2-1/2 hours/N<sub>2</sub>. The reaction was then quenched at 0° to 5°C with 2N HCl acid, and then diluted with CHCl<sub>3</sub>. The organic 15 layers were separated, washed with H<sub>2</sub>O 3 times, then with saturated NaCl solution, and finally dried over MgSO<sub>4</sub>. Filtered, and the organic phase was evaporated under vacuum to give 216.0 mg of crude product.

20 The crude product was chromatographed on 20.0 g of E.M. silica gel column, using 70:30(CHCl<sub>3</sub>-acetone) as eluant.

Yield of single spot material was 126.3 mg of the above-titled compound, m.pt. 271-271.5°C.

Calcd. for C<sub>19</sub>H<sub>29</sub>O<sub>2</sub>N: FAB 304; Found 304.

25 NMR in CDCl<sub>3</sub> confirmed the above structure.

EXAMPLE 16

17 $\beta$ -Formyl-4-aza-5 $\alpha$ -androst-1-ene-3-one

30 Into a 100.0 ml dry flask was placed 1.3 ml of oxalyl chloride (2 M in CH<sub>2</sub>Cl<sub>2</sub>) with 50.0 ml of dry CH<sub>2</sub>Cl<sub>2</sub>/N<sub>2</sub>. The above solution was cooled to -78°C and 338  $\mu$ l of DMSO was added dropwise via

-36-

syringe/ $N_2$ . The mixture was stirred at  $-78^\circ C/N_2$  for 30 minutes, and a solution of above-prepared alcohol from Example 15, i.e.  $17\beta$  hydroxymethyl-4-aza-5 $\alpha$ -androst-1-ene-3-one (256.9 mg in 15.0 ml of dry  $CH_2Cl_2/N_2$  was added via syringe. The reaction was allowed to progress for one hour at  $-78^\circ C/N_2$ . After an hour at  $-78^\circ C$ , was added 1 ml of dry triethylamine at a rapid rate. Reaction was raised slowly to R.T./ $N_2$  with stirring, the resulting yellow solution was then poured into 50.0 ml of cold water. The organic layers were washed with a saturated solution of  $NaHCO_3$ , and then with a saturated solution of  $NaCl$ . Dried over  $MgSO_4$ , evaporated the solvent under vacuum to give 172.4 mg of crude product. The crude product was chromatographed on 60.0 g silica gel column using 70:30 ( $CHCl_3$ -acetone), to give a single spot material. Crystallization from  $EtOAc$  afforded the above-titled compound, 37.7 mg, m.pt. 258-259°C.

20

EXAMPLE 17

Synthesis of diastereoisomeric  
 $17\beta(\alpha\text{-hydroxybenzyl})$ -4-  
aza-5 $\alpha$ -androst-1-ene-3-ones

25

—  
26.3 of above-prepared formyl derivative (from Example 16) was dissolved in 7.0 ml of dry  $THF/N_2$ . The solution was cooled to  $-78^\circ C/N_2$ , and 131  $\mu l$  of phenyl magnesium bromide (Aldrich reagent) (3 equivalents) in dry  $THF$  was added dropwise via syringe/ $N_2$ . Allowed the reaction to proceed for 1 hour/ $N_2$  at  $-78^\circ C$  and then at R.T. for addition hour/ $N_2$ .

The reaction was quenched at 0-5°C with 2.5N  $HCl$ , and then diluted with  $CHCl_3$ . Organic layers

-37-

were separated, washed 3 times with water; 3 times with saturated NaCl solution, dried over MgSO<sub>4</sub>. Filtered and evaporated in vacuum to dryness to afford 28.6 mg of crude product. The crude product  
5 was filtered through a 1  $\mu$ m Teflon filter and purified by HPLC on a Whitman Portasil 10 column using 70:30(CHCl<sub>3</sub>-acetone). NMR analysis, as well as, peak heights from HPLC analysis indicated this product to be a 1:1 mixture of diastereoisomers. The  
10 FAB mass spectrum clearly indicated correct M<sup>+</sup>+1 for both isomers, namely 380 units. The polar isomer whose purity was 99.5%, m.pt. 289-289.5°C, was crystallized from EtOAc and showed a single spot material on TLC.

15 Anal. Calcd. for C<sub>25</sub>H<sub>33</sub>NO<sub>2</sub>•1/4 H<sub>2</sub>O;  
C, 78.39; H, 8.81; N, 3.65.  
Found: C, 78.11; H, 8.65; N, 3.58.


20 The less polar isomer whose purity was 98%, m.pt. 300-301°C showed a single spot material on TLC. The polar isomer showed by NMR(CDCl<sub>3</sub>): CH<sub>3</sub> at C-18 was deshielded (0.89 $\delta$ ) as compared to the less polar CH<sub>3</sub> at C-18 at (0.69 $\delta$ ). The other interesting observation, the benzilic proton for the polar  
25 isomer was also deshielded (4.5 $\delta$ ) versus (4.95 $\delta$ ). The olefinic proton at C-1 showed deshielding effects for the polar isomer at (6.81 $\delta$ ) to (6.62 $\delta$ ). From the above data, the two isomers showed distinctly different physical properties.

-38-

WHAT IS CLAIMED IS:

1. A method of treating baldness comprising  
5 administering to a person in need of such treatment a  
pharmaceutical composition containing a therapeuti-  
cally effective amount of compound of the formula:

10



15

wherein

20

R is selected from hydrogen, methyl and ethyl, and

25

R<sup>2</sup> is phenyl substituted with one or more of -OH, -OC<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkyl, -(CH<sub>2</sub>)<sub>m</sub>OH, -(CH<sub>2</sub>)<sub>n</sub> COOH, including protected hydroxy, where m is 1-4, n is 1-3, providing C<sub>1</sub>-C<sub>4</sub> alkyl is only present when one of the above oxygen-containing radicals is present, wherein the dotted line represents a double bond which can be present, and pharmaceutically acceptable salts and esters thereof.

30

-39-


2. The method of Claim 1 wherein said pharmaceutical composition is administered topically and said compound is present in said pharmaceutical composition in an amount of from about 0.1% to about 15% by weight.

3. The method of Claim 1 wherein said pharmaceutical composition is administered systemically and said compound is present in said pharmaceutical composition in an amount of from about 0.01 mg to about 50 mg.

4. A method of treating baldness comprising administering to a person in need of such treatment a pharmaceutical composition containing a therapeutically effective amount of a compound of the formula:

20

25



30

wherein

R is selected from hydrogen, methyl and ethyl, and

-40-

R<sup>2</sup> is phenyl substituted with one or more of  
-OH, -OC<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkyl,  
-(CH<sub>2</sub>)<sub>m</sub>OH, -(CH<sub>2</sub>)<sub>n</sub> COOH, including  
protected -OH, where m is 1-4, n is 1-3,  
5 providing C<sub>1</sub>-C<sub>4</sub> alkyl is only present when  
one of the above oxygen-containing radicals  
is present, wherein the dotted line  
represents a double bond which can be  
present, and pharmaceutically acceptable  
10 salts and esters thereof.

5. The method of Claim 4 wherein said  
pharmaceutical composition is administered topically  
and said compound is present in said pharmaceutical  
15 composition in an amount of from about 0.1% to about  
15% by weight.

6. The method of Claim 4 wherein said  
pharmaceutical composition is administered  
20 systemically and said compound is present in said  
pharmaceutical composition in an amount of from about  
0.01 mg to about 50 mg.

25

30

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US93/00409

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(5) :A61K 31/56  
US CL :514/177

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/177

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CHEMICAL ABSTRACTS (STN) use of the claimed compounds as antiandrogens or for the treatment of alopecia or baldness

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	Chemical Abstracts 114:247583s, 1991.	1-6
Y	<u>Illustrated Stedman's Medical Dictionary</u> (24th edition), 1982, WILLIAMS and WILKINS, See especially page 45.	1-6
Y	<u>The Pharmacological Basis of Therapeutics</u> , (8th edition), 1991, (GOODMAN GILMAN ET AL.) See especially page 1587.	1-6
A,P	US, A, 5,143,909 (WEINTRAUB ET AL.), 01 September 1992, See claims especially, columns 11 and 12.	1-6
A	US, A, 4,859,681 (RASMUSSEN ET AL.) 22 August 1989, See especially the abstract.	1-6

Further documents are listed in the continuation of Box C.  See patent family annex.

Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
document defining the general state of the art which is not considered to be part of particular relevance		
"E"	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step
"L"		when the document is taken alone
document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O"		
document referring to an oral disclosure, use, exhibition or other means	"&"	document member of the same patent family
"P"		
document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search	Date of mailing of the international search report
13 MAY 1993	07 JUN 1993

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. NOT APPLICABLE

Authorized officer

M. MOEZIE

Telephone No. (703) 308-1235

THIS PAGE BLANK (USPTO)

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**

**THIS PAGE BLANK (USPTO)**